Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ancitabine hydrochloride

The hydrochloride salt of a cytarabine congener prodrug with antineoplastic activity. Upon administration, ancitabine is slowly hydrolyzed into cytarabine. Subsequently, cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. Cytarabine agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Compared to cytarabine, a more prolonged, consistent cytarabine-mediated therapeutic effect may be achieved with ancitabine because of the slow hydrolytic conversion of ancitabine to cytarabine.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ancytabine hydrochloride
cycloCMP hydrochloride
cyclocytidine
cyclocytidine HCL
cyclocytidine hydrochloride
Foreign brand name:Ancid
Code name:U-33, 624A
Chemical structure:6H-furo(2',3':4,5)oxazolo(3,2-a)pyrimidine-2-methanol,2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-,(2R(2alpha,3beta,3a beta,9a beta))
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search